IP Library › Granted Patent US 12,662,529
Granted Patent B2
US 12,662,529 · App. 19/048,808 · Granted Jun 23, 2026

Production of biosimilar ustekinumab in CHO cells

Inventors: Susanne Pippig (Munich, DE); Carsten Brockmeyer (Marzling, DE)
Assignee: FYB202 PROJECT GMBH
C07K16/244A61K9/0019A61K47/183A61K47/20A61K47/22A61K47/26A61K2039/54C07K2317/14C07K2317/21C07K2317/41C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,662,529
App. No.
19/048,808
Filed
Feb 7, 2025
Granted
Jun 23, 2026
Kind
B2
Examiner
KIM, YUNSOO
Art Unit
1641
USPC
424/133.1
Abstract

The present invention relates to a method for producing an ustekinumab antibody in CHO cells. It further relates to the use of the produced antibody in the treatment of plaque psoriasis, psoriatic arthritis and inflammatory bowel disease.

Claims (72)

1 . A method of producing a recombinant ustekinumab antibody comprising the heavy chain and the light chain of ustekinumab, wherein the heavy chain and the light chain together form the recombinant ustekinumab antibody, the method comprising,

a) culturing Chinese Hamster Ovary (CHO) host cells, genetically modified to express the heavy chain and the light chain of ustekinumab, in a suitable culture medium under conditions that allow the cells to express the heavy chain and the light chain and to form the recombinant ustekinumab antibody,

b) harvesting the recombinant ustekinumab antibody from the host cell culture to obtain a recombinant ustekinumab antibody preparation, and

c) purifying the recombinant ustekinumab antibody preparation obtained from harvesting by one or more purification step(s),

wherein the recombinant ustekinumab antibody is a biosimilar of the ustekinumab reference product, wherein the ustekinumab reference product is produced in murine myeloma cells.

2 . The method of claim 1 , wherein the heavy chain of the recombinant ustekinumab has the sequence according to SEQ ID No. 1 and the light chain of the ustekinumab has the sequence according to SEQ ID No. 2.

3 . The method of claim 1 , wherein the ustekinumab reference product comprises a heavy chain according to SEQ ID No. 1 and a light chain according to SEQ ID No. 2.

4 . The method of claim 1 , wherein the CHO host cells are CHO-Kl cells or cells derived therefrom.

5 . The method of claim 1 , wherein the recombinant ustekinumab antibody is produced in large scale.

6 . The method of claim 1 , comprising combining the recombinant ustekinumab antibody from the recombinant ustekinumab antibody preparation one or more pharmaceutically acceptable excipient(s) to obtain a recombinant ustekinumab antibody drug product.

7 . The method of claim 6 , wherein the one or more pharmaceutically acceptable excipient(s) is/are selected from the group consisting of sucrose, L-histidine, L-histidine monohydrochloride monohydrate and polysorbate 80.

8 . The method of claim 6 , wherein the one or more pharmaceutically acceptable excipient(s) is/are selected from the group consisting of sucrose, L-histidine, L-histidine monohydrochloride monohydrate, methionine, EDTA disodium salt dihydrate and polysorbate 80.

9 . The method of claim 7 , wherein the recombinant ustekinumab antibody drug product comprises 90 mg/mL recombinant ustekinumab antibody and one or more pharmaceutically acceptable excipient(s) selected from the group consisting of 76 mg/mL sucrose, 1 mg/mL L-histidine/L-histidine monohydrochloride monohydrate and 0.04 mg/mL polysorbate 80.

10 . The method of claim 8 , wherein the recombinant ustekinumab antibody drug product comprises 5 mg/mL recombinant ustekinumab antibody and one or more pharmaceutically acceptable excipient(s) selected from the group consisting of 85 mg/mL sucrose, 1.8 mg/mL L-histidine/L-histidine monohydrochloride monohydrate, 0.4 mg/mL methionine, 0.02 mg/mL EDTA disodium salt dihydrate and 0.4 mg/mL polysorbate 80.

11 . The method of claim 1 , comprising determining that the recombinant ustekinumab antibody in the recombinant ustekinumab antibody preparation obtained in step b) or c) meets one or more of the following criteria (i) to (ii):

(i) binding to IL-23 differs from that of the ustekinumab reference product by not more than 20% or,

(ii) binding to IL-12 differs from that of the ustekinumab reference product by not more than 20%.

12 . The method of claim 1 , comprising determining that the recombinant ustekinumab antibody in the recombinant ustekinumab antibody preparation obtained in step b) or c) meets one or more of the following criteria (iii) to (vi):

(iii) lower percentage of recombinant ustekinumab antibody molecules comprise c-terminal lysine,

(iv) higher percentage of sialic acid being N-acetylneuraminic acid, (v) lower percentage of sialic acid being N-glycolylneuraminic acid or,

(vi) lower content of afucosylated glycoforms, as compared to the ustekinumab reference product.

13 . The method of claim 1 , comprising determining that the recombinant ustekinumab antibody in the recombinant ustekinumab antibody preparation obtained in step b) or c) meets one or more of the following criteria (vii) to (x):

(vii) greater than 90% of the sialic acid being N-acetylneuraminic acid,

(viii) less than 10% of the sialic acid being N-glycolylneuraminic acid,

(ix) content of afucosylated glycoforms is less than 8% or,

(x) content of terminal a-galactose is less than or equal to 0.1%.

14 . The method of claim 11 , wherein the binding to IL-23, and/or IL-12 is determined by Enzyme linked immunosorbent assay (ELISA) or bio-layer interferometry.

15 . The method of claim 12 , wherein the recombinant ustekinumab antibody molecules comprising c-terminal lysine are measured by cation exchange chromatography (CEX).

16 . The method of claim 12 , wherein the N-acetylneuraminic acid and N-glycolylneuraminic acid are measured by hydrophilic interaction liquid chromatography-ultra performance liquid chromatography HILIC-UPLC.

17 . The method of claim 13 , wherein the N-acetylneuraminic acid, N-glycolylneuraminic acid afucosylated glycoforms, and a-galactose are measured by hydrophilic interaction liquid chromatography-ultra performance liquid chromatography HILIC-UPLC.

18 . A biosimilar recombinant ustekinumab antibody produced by the method of claim 1 .

19 . The biosimilar recombinant ustekinumab of claim 18 , wherein the biosimilar recombinant ustekinumab antibody meets one or more of the following criteria:

(i) binding to IL-23 differs from that of the ustekinumab reference product by not more than 20% or,

(ii) binding to IL-12 differs from that of the ustekinumab reference product by not more than 20%.

20 . The biosimilar recombinant ustekinumab antibody of claim 18 , wherein the biosimilar recombinant ustekinumab antibody meets one or more of the following criteria:

(iii) lower percentage of recombinant ustekinumab antibody molecules comprise c-terminal lysine,

(iv) higher percentage of sialic acid being N-acetylneuraminic acid,

(v) lower percentage of sialic acid being N-glycolylneuraminic acid,

(vi) lower content of afucosylated glycoforms,

as compared to the ustekinumab reference product.

21 . The biosimilar recombinant ustekinumab antibody of claim 18 , wherein the biosimilar recombinant ustekinumab antibody meets one or more of the following criteria:

(vii) greater than 90% of the sialic acid being N-acetylneuraminic acid,

(viii) less than 10% of the sialic acid being N-glycolylneuraminic acid,

(ix) content of afucosylated glycoforms is less than 8% or,

(x) content of terminal a-galactose is less than or equal to 0.1%.

22 . A biosimilar recombinant ustekinumab antibody produced in CHO cells, wherein the recombinant ustekinumab antibody is a biosimilar of a ustekinumab reference product, wherein the ustekinumab reference product is produced in murine myeloma cells.

23 . The biosimilar recombinant ustekinumab antibody of claim 22 , comprising a heavy chain and a light chain, wherein the heavy chain has the sequence according to SEQ ID No. 1 and the light chain has the sequence according to SEQ ID No. 2, wherein the recombinant ustekinumab antibody is a biosimilar of the ustekinumab reference product, wherein the ustekinumab reference product is produced in murine myeloma cells.

24 . The biosimilar recombinant ustekinumab antibody of claim 22 , comprising a heavy chain and a light chain, wherein the heavy chain has the sequence according to SEQ ID No. 1 and the light chain has the sequence according to SEQ ID No. 2, wherein the recombinant ustekinumab antibody is a biosimilar of the ustekinumab reference product, wherein the ustekinumab reference product is produced in murine myeloma cells, and wherein the ustekinumab reference product comprises a heavy chain according to SEQ ID No. 1 and a light chain according to SEQ ID No. 2.

25 . The biosimilar recombinant ustekinumab antibody of claim 22 that meets one or more of the following criteria:

(i) binding to IL-23 differs from that of the ustekinumab reference product by not more than 20%,

(ii) binding to IL-12 differs from that of the ustekinumab reference product by not more than 20%,

(iii) lower percentage of recombinant ustekinumab antibody molecules comprise c-terminal lysine as compared to the ustekinumab reference product,

(iv) higher percentage of sialic acid being N-acetylneuraminic acid as compared to the ustekinumab reference product,

(v) lower percentage of sialic acid being N-glycolylneuraminic acid as compared to the ustekinumab reference product,

(vi) lower content of afucosylated glycoforms as compared to the ustekinumab reference product,

(vii) greater than 90% of the sialic acid being N-acetylneuraminic acid,

(viii) less than 10% of the sialic acid being N-glycolylneuraminic acid,

(ix) content of afucosylated glycoforms is less than 8% or,

(x) content of terminal a-galactose is less than or equal to 0.1%,

wherein the ustekinumab reference product is produced in murine myeloma cells.

26 . The biosimilar recombinant ustekinumab antibody of claim 22 , having a heavy chain according to SEQ ID No. 1 and a light chain according to SEQ ID NO: 2 that meets one or more of the following criteria:

(i) binding to IL-23 differs from that of the ustekinumab reference product by not more than 20%,

(ii) binding to IL-12 differs from that of the ustekinumab reference product by not more than 20%,

(iii) lower percentage of recombinant ustekinumab antibody molecules comprise c-terminal lysine as compared to the ustekinumab reference product,

(iv) higher percentage of sialic acid being N-acetylneuraminic acid as compared to the ustekinumab reference product,

(v) lower percentage of sialic acid being N-glycolylneuraminic acid as compared to the ustekinumab reference product,

(vi) lower content of afucosylated glycoforms as compared to the ustekinumab reference product,

(vii) greater than 90% of the sialic acid being N-acetylneuraminic acid,

(viii) less than 10% of the sialic acid being N-glycolylneuraminic acid,

(ix) content of afucosylated glycoforms is less than 8% or,

(x) content of terminal a-galactose is less than or equal to 0.1%,

wherein the ustekinumab reference product is produced in murine myeloma cells, and wherein the ustekinumab reference product comprises a heavy chain according to SEQ ID No. 1 and a light chain according to SEQ ID No. 2.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2026
From: PIPPIG, SUSANNE; BROCKMEYER, CARSTEN
To: FYB 202 PROJECT GMBH
Reel/Frame 074222/0190 →
Priority Claims (1)
EP 16182661 · Aug 3, 2016 · regional
Continuity (3)
Continuation 17572350 · Jan 10, 2022
Continuation 16322846
Related Publication 20250230231A1 · Jul 17, 2025
References Cited (43)
US 8962804B2 · Williams · 2015 [cited by examiner]
US 12098196B2 · Pippig et al. · 2024 [cited by applicant]
US 20050009097A1 · Better · 2005 [cited by examiner]
US 20130126742A1 · Hayun et al. · 2013 [cited by applicant]
US 20130216742A1 · DeMartino · 2013 [cited by examiner]
US 20200347126A1 · Pippig et al. · 2020 [cited by applicant]
US 20220204607A1 · Pippig et al. · 2022 [cited by applicant]
EP 3059319A1 · 2016 [cited by applicant]
EP 3493843A1 · 2019 [cited by applicant]
WO WO2002012500A2 · 2002 [cited by applicant]
WO WO2012012271A2 · 2012 [cited by examiner]
WO WO2012149197A2 · 2012 [cited by applicant]
WO WO2015053523A1 · 2015 [cited by applicant]
Bort, J.A., et al., “CHO-K1 host cells adapted to growth in glutamine-free medium by FACS-assisted evolution,” Biotechnology Journal 5:1090-1097, Wiley-VCH Verlag GMBH, Germany (2010). [cited by applicant]
Chung, C.H., et al., “Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose,” N Eng J. Med 358(11):1109-1117, Massachusetts Medical Society, United States (2008). [cited by applicant]
Diaz, S.L., et al., “Sensitive and Specific Detection of the Non-Human Sialic Acid N-Glycolylneuraminic Acid In Human Tissues and Biotherapeutic Products,” PLoS One 4(1):e4241, Public Library of Science, United States (… [cited by applicant]
Dumont, J., et al., “Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives,” Crit. Rev. Biotechnol. 36(6): 1110-1122, Taylor & Francis, United States (2015). [cited by applicant]
Gramer, M.J., et al., “Modulation of Antibody Galactosylation Through Feeding of Uridine, Manganese Chloride, and Galactose,” Biotechnol. Bioeng. 108(7): 1591-1602, Wiley Online Library, United States (2011). [cited by applicant]
Kaneko, Y., et al., “Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation,” Sciencemag.org 313:670-673, American Association for the Advancement of Science, United States (2006). [cited by applicant]
Kao, T-F., et al., “Genetics Of Somatic Mammalian Cells, Vii. Induction And Isolation Of Nutritional Mutants In Chinese Hamster Cells,” Genetics: 1275-1281, Genetics Society of America, United States (1968). [cited by applicant]
Kaufman, R.J., et al., “Overview of Vector Design for Mammalian Gene Expression,” Molecular Biotechnology 16(2):151-160, Springerlink, United States (2000). [cited by applicant]
Makrides, S.C., “Components of Vectors for gene Transfer and Expression in Mammalian Cells,” Protein Expression and Purification 17:183-202, Academic Press, United States (1999). [cited by applicant]
Onitsuka, M., et al., “Enhancement of sialylation on humanized IgG-like bispecific antibody by overexpression of α2,6-sialyltransferase derived from Chinese hamster ovary cells,” Appl Microbiol Biotechnol 94:69-80, Spri… [cited by applicant]
Padler-Karavani, et al., “Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease,” Glycobiology 18(10):818-830, Oxford Journals, England (2008… [cited by applicant]
Raju, T.S., et al., “Galactosylation variations in marketed therapeutic antibodies,” mABS 4(3):385-391, Landes Biosciences, United States (2012). [cited by applicant]
Rohrer, J.S., et al., “Analysis of the N-acetylneuraminic acid and N-glycolylneuraminic acid contents of glycoproteins by high-pH anion-exchange chromatography with pulsed amperometric detection (HPAEC/PAD),” Glycobiolo… [cited by applicant]
Ruhaak, L.R., et al., “Glycan labeling strategies and their use in identification and quantification,” Anal Bioanl Chem 397:3457-3481, Springerlink, United States (2010). [cited by applicant]
Scallon, B.J., et al., “Higher Levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality,” Molecular Immunology 44:1524-1534, Elsevier (2007). [cited by applicant]
Tijo, J.H., et al., “Genetics of Somatic Mammalian Cells: II Chromosomal Constitution of Cells in Tissue Culture,” J Exp Med 108(2): 259-268, Rockefeller University Press, United States (1958). [cited by applicant]
Yu, C., et al., “At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody,” Scientific Reports 6:20029, Nature Publishing, England (2016). [cited by applicant]
Benson, J.M., et al., “Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders,” [cited by applicant]
Dhara, V.G., et al., “Recombinant Antibody Production in CHO and NS0 Cells: Differences and Similarities,” [cited by applicant]
Walsh, G., “Biopharmaceutical benchmarks 2018,” Nat Biotechnology 36(12):1136-1145, Nature Publishing Group, United Kingdom (2018). [cited by applicant]
European Medicines Agency, Stelara, INN-ustekinumab, Annex I, Summary of Product Characteristics, 182 pages. [cited by applicant]
Formycon AG, “Formycon's Biosimilar U stekinumab Candidate Fyb202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study,” accessed at https://www.formycon.com/en/blog/press-release/formycons-biosim… [cited by applicant]
Borys, M.C., et al., “Effects of culture conditions on N-glycolylneuraminic acid (Neu5Gc) content of a recombinant fusion protein produced in CHO cells,” Biotechnol Bioeng 105(6):1048-1057, Wiley, United States (Apr. 20… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2017/069522, European Patent Office, Netherlands, mailed on Oct. 26, 2017, 17 pages. [cited by applicant]
Janssen, “ustekinumab New Zealand Data Sheet,” www.medsafe.govt.nz, accessed at https://www.medsafe.govt.nz/profs/datasheet/s/stelarainj.pdf, accessed on Feb. 3, 2025, 44 pages. [cited by applicant]
Read, E.K., et al., “Industry and regulatory experience of the glycosylation of monoclonal antibodies,” Biotechnol Appl Biochem. 58(4):213-219, Wiley, United States (Jul.-Aug. 2011). [cited by applicant]
Sandborn, W.J., et al. “Ustekinumab induction and maintenance therapy in refractory Crohn's disease,” N Engl J Med. 367(16):1519-1528, Massachusetts Medical Society, United States (Oct. 2012). [cited by applicant]
Schwaigerlehner, L., “Antibody gene expression in CHO cells with recombinase mediated cassette exchange,” University of Natural Resources and Life Sciences Vienna, Austria (Nov. 2015), 105 pages. [cited by applicant]
Xu, X., et al., “The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line,” Nat Biotechnol. 29(8):735-741, Springer Nature, Germany (Jul. 2011). [cited by applicant]
Zhang, L., et al., “Recombinase-mediated cassette exchange (RMCE) for monoclonal antibody expression in the commercially relevant CHOK1SV cell line,” Biotechnol Prog. 31(6):1645-1656, Wiley, United States (Oct. 2015). [cited by applicant]